Effect of bempedoic acid on cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease

20260 citationsJournal Articlehybrid Open Access

Authors

Vivian de Jong · University Medical Center Utrecht

S E Nissen · Cleveland Clinic

William J. Sasiela · Esperion Therapeutics (United States)

Michael Li · Esperion Therapeutics (United States)

LeAnne T. Bloedon · Esperion Therapeutics (United States)

A Michael Lincoff · Cleveland Clinic

S J Nicholls

Abstract

Liver steatosis and fibrosis assessed with non-invasive tests are associated with an increased risk of MACE4. Bempedoic acid reduced MACE4 risk, with an additional benefit in patients with elevated steatosis scores.

Topics & Keywords

Liver Disease Diagnosis and Treatment Liver Disease and Transplantation Fatty Acid Research and Health

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Preventive Cardiology

DOI: 10.1093/eurjpc/zwag102

Field-Weighted Citation Impact: 0.00